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Human T-lymphotropic virus types I and II (HTLV-I and
-II) cause myelopathy; HTLV-I, but not HTLV-II, causes
adult T-cell leukemia. Whether HTLV-II is associated with
other diseases is unknown. Using survival analysis, we
studied medical history data from a prospective cohort of
HTLV-I– and HTLV-II–infected and –uninfected blood
donors, all HIV seronegative. A total of 152 HTLV-I, 387
HTLV-II, and 799 uninfected donors were enrolled and fol-
lowed for a median of 4.4, 4.3, and 4.4 years, respectively.
HTLV-II participants had significantly increased incidences
of acute bronchitis (incidence ratio [IR] = 1.68), bladder or
kidney infection (IR = 1.55), arthritis (IR = 2.66), and asth-
ma (IR = 3.28), and a borderline increase in pneumonia (IR
= 1.82, 95% confidence interval [CI] 0.98 to 3.38). HTLV-I
participants had significantly increased incidences of blad-
der or kidney infection (IR = 1.82), and arthritis (IR = 2.84).
We conclude that HTLV-II infection may inhibit immunolog-
ic responses to respiratory infections and that both HTLV-I
and -II may induce inflammatory or autoimmune reactions.
H
uman T-lymphotropic virus types I and II (HTLV-I
and -II) are presumed to have derived from primate T-
lymphotropic viruses with which they share significant
nucleotide sequence homology (1). They are transmitted
by sexual intercourse; by parenteral modes such as
unscreened blood or shared injection equipment; and from
mother to child, predominantly by breast feeding (2–4).
HTLV-I has been causally associated with adult T-cell
leukemia and HTLV-associated myelopathy. HTLV-II has
also been associated with HTLV-associated myelopathy,
but not with leukemia (5).
Other possible health outcomes of chronic HTLV-I and
-II infection have not yet been adequately investigated.
Patients with adult T-cell leukemia  may develop oppor-
tunistic infections such as Pneumocystis carinii pneumo-
nia (6) or Strongyloides superinfection (7), but clinical
immunodeficiency does not appear to develop in most per-
sons with chronic HTLV-I or -II  infection. On the con-
trary, syndromes suggestive of increased immunologic
response such as uveitis (8), pneumonitis (9,10), and
rarely, cases of lymphocytic arthritis (11,12) have been
reported, although only uveitis has been epidemiologically
associated with HTLV-I (8). Investigators in Japan have
linked HTLV-I to a higher occurrence of various medical
conditions (13) and virus-associated malignancies (14).
Other investigators have reported an association between
HTLV-II and pneumonia among injection drug users (15).
Case series and cross-sectional studies of HTLV-I and -
II disease outcomes are vulnerable to potential bias and
confounding. We have prospectively followed a large
cohort of former blood donors with well-documented
HTLV-I and -II infection at enrollment, and a similar group
of uninfected donors, all of whom are HIV seronegative.
We report on the occurrence of various disease outcomes
in this cohort after a median follow-up of 4.3 years.
Methods
Study Design and Participants
This study is a prospective, multicenter cohort of per-
sons with HTLV-I and -II infections, which were detected
at the time of attempted blood donation at five U.S. blood
centers and comparable HTLV–seronegative donors.
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We determined HTLV serostatus by obtaining enzyme
immunoassay test results followed by confirmatory
Western blot. A central laboratory performed HTLV-I ver-
sus -II typing with a type-specific serologic assay, poly-
merase chain reaction (PCR), or both, as previously
described (18). Unequivocal results from the type-specific
serologic assay correlated well with those from the poly-
merase chain reaction assay. All participants were seroneg-
ative for HIV when baseline test were performed. For most
participants, hepatitis C virus antibody status was not
available at the time of enrollment.
Disease Endpoints
Each visit with a study nurse consisted of an interview-
er-administered health history questionnaire and phleboto-
my of blood for complete blood count and other studies.
Selected diagnoses (cancer, neurologic and autoimmune
conditions) reported on the questionnaire triggered
requests for confirmatory medical records. We included
nine conditions or diseases (pneumonia, acute bronchitis,
bladder or kidney infection, arthritis, hypertension, asth-
ma, cancer, diabetes, and thyroid disease) and eight symp-
toms (trouble walking, climbing, or rising from chair;
incontinence; pre- or post-void urgency; lymphadenopa-
thy; night sweats; weight loss; foot paresthesias; and impo-
tence [males]) in the data analysis.
Statistical Analysis
We used the Kaplan-Meier product limit method to cal-
culate the unadjusted probability of disease-free survival
during the study period for each disease outcome by HTLV
status. Survival time was defined as the number of days
from the baseline visit until the date that an adverse health
outcome was first diagnosed or the end of observation. We
performed the log-rank test to assess the differences in dis-
ease-free survival time (days) between HTLV-seronegative
participants and HTLV-I– or HTLV-II–infected partici-
pants, respectively. 
To adjust for possible confounding factors, we per-
formed multivariable analysis with HTLV status as an
independent variable, survival time as a dependent vari-
able, and possible confounding factors as covariates. In
constructing the survival analysis models, we considered a
number of covariates, which are described as follows:
demographic variables (forced into all models), education,
smoking history (pack-years, forced into the models for
bronchitis and pneumonia), alcohol consumption, blood
center, community versus autologous donation type, injec-
tion drug use (except in models for arthritis, hypertension,
cancer, neurologic and urologic symptoms), parity (in
models for urinary symptoms, bladder and kidney infec-
tions, and  in females only), and number of sex partners (in
model for bladder and kidney infections only). Using a
backward selection process, all these covariates were
added to the initial model, but only covariates with signif-
icant independent associations themselves (p < 0.05), or
which substantively modified HTLV incidence ratio, were
retained in the final model. We did not include interaction
terms because similar analyses of data from prior cohort
visits had indicated the absence of significant interaction.
To examine the differences in the cumulative number of
episodes of pneumonia, bronchitis, and bladder or kidney
infection by HTLV status, we used the negative binomial
model, a generalization of the Poisson model, to compute
incidence rate ratios (RR) with 95% confidence interval
(CI) for each of these outcomes. This model took into
account that the recurrence of the disease in a participant
may be associated with both the overall disease incidence
and its previous occurrence in that participant. We also
adjusted for possible confounding factors using the same
modeling strategy as for the survival analyses. 
For the analysis of symptoms, we calculated unadjust-
ed and adjusted odds ratio (OR) with 95% CI for any
occurrence of each symptom by HTLV status by using
logistic regression models. To adjust for possible con-
founding, we added other possible confounding factors as
covariates to the models by using the same approach as in
the survival analyses. All analyses were performed using
Statistical Analysis System (SAS) software (19).
Results
Study Population and Follow-up 
During the initial visits in 1990 through 1992, we
enrolled 154 HTLV-I, 387 HTLV-II, and 799 HTLV
seronegative persons. Two HTLV-I participants were
excluded from this analysis because they did not complete
the screening physical examination at the initial visit.  The
baseline characteristics of the study population are given in
Table 1. The HTLV groups and seronegative participants
were comparable with respect to age, sex, race or ethnici-
ty, blood center visited, and type of blood donation (autol-
ogous versus allogeneic), except for slightly higher pro-
portions of blacks among the HTLV-I group and Hispanics
among the HTLV-II group. The HTLV-II group had the
lowest socioeconomic status, as indicated by educational
attainment and income, and the HTLV-I group had inter-
mediate status. Pack-years of cigarette smoking and
amount of alcohol intake were higher in the HTLV-II
group. Consistent with the recognized epidemiologic risk
factors for HTLV-I and -II infection (3,4), the HTLV-I and
-II groups had more lifetime sexual partners than seroneg-
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pants had a lifetime history of injection drug use, although
only 4.4% of the HTLV-II group admitted to current injec-
tion drug use.
We present data through the third study visit in 1995
through 1996. Median follow-up time was 4.3 years for all
1,338 participants, including those with no follow-up.
Median follow-up did not differ by HTLV status and was
4.4 years for the HTLV-I group, 4.3 years for the HTLV-II
group, and 4.4 years for the HTLV-seronegative group. 
HTLV-I Findings
Compared to seronegative persons, HTLV-I–infected
persons were more likely to have a new diagnosis of blad-
der or kidney infection (p = 0.009) and arthritis (p =
0.0002) (Figure). Among the HTLV-I–infected persons,
two had asthma; an insufficient number to test the differ-
ence relative to seronegative persons. The HTLV-I partici-
pants showed no statistically significant differences in the
incidence of pneumonia, acute bronchitis, and hyperten-
sion, cancer, diabetes, and thyroid disease (data not
shown).
The number of incident cases diagnosed (limited to one
case per person) and the unadjusted and adjusted incidence
ratios (IR) for several diagnoses are given in Table 2.
Compared with results for seronegative persons, and after
multivariable adjustment for relevant confounding vari-
ables, HTLV-I infection was associated with bladder or
kidney infection (IR 1.82, 95% CI 1.19 to 2.77) and arthri-
tis (IR 2.84, 95% CI 1.51 to 5.33). The risks of developing
pneumonia, acute bronchitis, hypertension, and cancer
were not significantly increased. Too few cases of asthma
(n = 2), thyroid disease (n = 1), and diabetes mellitus (n =
5) existed among the HTLV-I participants to perform sur-
vival analysis. 
To further investigate the occurrence of infectious dis-
eases, we also analyzed the incidence density of three
infectious diseases by HTLV status, whether or not each
diagnosis was a first or recurrent case (Table 3).  In the
incidence density analysis (Table 3), an average of 1.75
cases of bladder or kidney infection occurred per HTLV-I
participant over the 4.4-year median follow-up time, com-
pared with 0.63 per seronegative participant over the same
period. The unadjusted and adjusted RRs for the HTLV-I
group were significantly greater than unity for bladder or
kidney infection. HTLV-I participants had increased preva-
lence rates of neurologic symptoms, self-reported lym-
phadenopathy, and night sweats, but they reported weight
loss no more frequently than did HTLV-seronegative per-
sons (Table 4).
HTLV-II Findings
Disease-free survival curves for selected medical diag-
noses, by HTLV status, are represented in the Figure.
Compared to seronegative persons, HTLV-II–infected par-
ticipants were more likely to experience acute bronchitis (p
< 0.0001), bladder or kidney infection (p = 0.0008), arthri-
tis (p = 0.0003), and asthma (p = 0.0007); the likelihood of
acquiring pneumonia was increased but not significantly
(p = 0.08). Differences between the HTLV-II and HTLV-
seronegative participants in the incidence of cancer, hyper-
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Table 1. Characteristics of the multicenter, prospective human T-




(n = 152) 
HTLV-II 
(n = 387) 
HTLV 
negative 
(n = 799) 
Age (y)  No. (%)  No. (%)  No. (%) 
18–29  5 (3)  11 (3)  34  (4) 
30–39  28 (18)  104 (27)  171 (21) 
40–49  55 (36)  168 (43)  288 (36) 
50–59  32 (21)  73 (19)  175 (22) 
>60  32 (21)  31 (8)  131 (16) 
Sex       
Male  43 (28)  102 (26)  257 (32) 
Female  109 (72)  285 (74)  542 (68) 
Race/ethnicity       
Asian  20 (13)  8 (2)  60 (8) 
Black  61 (40)  125 (32)  248 (31) 
Hispanic  9 (6)  104 (27)  150 (19) 
Other  1 (1)  7 (2)  30 (4) 
White  59 (39)  140 (36)  309 (39) 
Unknown  2 (1)  3 (1)  2 (0) 
Education       
High school or less  45 (30)  135 (35)  129 (16) 
Some college  66 (43)  195 (51)  363 (46) 
College  30 (20)  45 (12)  181 (23) 
College (>4 years)  11 (7)  11  (3)  123 (15) 
Income       
<$30,000  46 (30)  144 (38)  167 (21) 
$30,000–49,999  51 (34)  120 (32)  221 (28) 
>$50,000  55 (36)  113 (30)  401 (51) 
Center       
1  32 (21)  51 (13)  122 (15) 
2  29 (19)  39 (10)  102 (13) 
3  44 (29)  206 (53)  345 (43) 
4  31 (20)  68 (18)  156 (20) 
5  16 (11)  23  (6)  74 (9) 
Blood donor type       
Autologous  28 (18)  39 (10)  111 (14) 
Allogeneic  124 (82)  348 (90)  688 (86) 
Smoking history (pack/y) 
Nonsmoker  74 (52)  125 (36)  413 (54) 
0–13   24 (17)  117 (33)  184 (24) 
>13  43 (31)  109 (31)  174 (23) 
Alcohol intake (average drinks per wk) 
Nondrinker  19 (13)  20 (6)  70  (9) 
0–1  58 (41)  134 (38)  352 (46) 
>1  64 (45)  200 (57)  339 (45) 
Lifetime sex partners       
<6  56 (38)  87 (23)  381 (49) 
>6  92 (62)  292 (77)  403 (51) 
Injection drug use       
Ever  148 (98)  294 (76)  787 (99) 
Ex-injection drug user  2 (1)  75 (19)  9  (1) 
Current injection drug user  1 (1)  17  (4)  1  (0) 
aMissing data (up to 6%, depending upon the variable) were excluded from the 
calculation of percentages. tension, diabetes, or thyroid disease were not statistically
significant.
The number of incident cases diagnosed (limited to one
case per participant), and the unadjusted and adjusted IRs,
for several diagnoses are given in Table 2. Compared with
results for seronegative participants, and after adjusting for
confounding variables, HTLV-II was associated with acute
bronchitis (OR 1.68, 95% CI 1.24 to 2.29), bladder or kid-
ney infection (OR 1.55, 95% CI 1.14 to 2.11), arthritis (OR
2.66, 95% CI 1.58 to 4.45), and asthma (OR 3.28, 95% CI
1.57 to 6.84). The association between HTLV-II infection
and pneumonia was of borderline statistical significance
(IR 1.82 , 95% CI 0.98 to 3.38). IRs for hypertension and
cancer were not increased for HTLV-II participants. Too
few cases of thyroid disease (n = 7) and diabetes mellitus
(n = 7) were found among the HTLV-II participants to per-
form survival analysis. 
In the incidence density analysis of recurrent infections,
an average of 0.21 cases of pneumonia, 1.10 cases of acute
bronchitis, and 1.25 cases of bladder or kidney infection
occurred among HTLV-II participants during their 4.3-year
median follow-up time (Table 3). The corresponding inci-
dence densities for the seronegative group were 0.08, 0.59,
and 0.63, respectively, over their 4.4 year median follow-
up time. Both unadjusted and adjusted RRs, calculated by
using negative binomial modeling, were significantly
greater than unity for all three diseases (Table 3).
Compared with seronegative participants, HTLV-II partic-
ipants had increased prevalence rates of several neurolog-
ic, lymphatic, and constitutional symptoms, but the preva-
lence of impotence (males) was not significantly increased
(Table 4). 
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Figure. Kaplan-Meier survival curves showing disease-free survival for one noninfectious and three infectious diseases, by human T-lym-
photropic virus (HTLV) status, through visits 2 and 3 of prospective observation. HTLV-I–infected (red triangles) and HTLV-II–infected
(green squares) participants are compared to HLTV-seronegative participants (blue diamonds), respectively. Panels are as follows: A)
pneumonia; B) acute bronchitis; C) bladder or kidney infection; and D) hypertension. The vertical axis scale has been compressed in
panel A because of the lower overall incidence of pneumonia.Discussion
In summary, HTLV-II–infected participants had a high-
er incidence of acute bronchitis, bladder or kidney infec-
tion, arthritis and asthma, and a higher incidence of pneu-
monia than did HTLV-seronegative participants followed
concurrently. The finding of a higher rate of these infec-
tious diseases among HTLV-II participants was supported
both by survival analysis, which considered only the first
diagnosis, and by negative binomial modeling, which con-
sidered both first and recurrent infections. HTLV-I partici-
pants had a higher incidence of bladder or kidney infection
and arthritis. Cancer incidence was not higher in either the
HTLV-I or HTLV-II participants compared to its incidence
in seronegative participants, although the number of cases
was small.
Our finding of a higher incidence of respiratory tract
infections among HTLV-II–infected persons is consistent
with most of the small number of other published clinical
studies on this topic. Robert-Guroff et al. found higher
rates of HTLV-II infection among injection drug users with
abscess than in those without abscess (20). In another
cross-sectional analysis, Modahl et al. found that injection
drug users with HTLV-II infection were more likely to
have been diagnosed with pneumonia, abscess, or lym-
phadenopathy (15), although a subsequent case-control
study did not find that either HTLV-II or HIV are risk fac-
tors for skin and soft tissue abscess among injection drug
users (21). LaGrenade et al. have documented an associa-
tion between HTLV-I infection and Staphylococcus- and
Streptococcus-related infective dermatitis among Jamaican
children (22). An independent nested case-control study of
pneumonia, abscess, and endocarditis among Baltimore
injection drug users found no association between these
infections and HTLV-II seropositivity (23). A number of
opportunistic co-infections have been reported in conjunc-
tion with HTLV-I infection, including Strongyloides hyper-
infection (7), P. carinii pneumonia (in patients with HTLV-
I–related adult T-cell leukemia) (6), and leprosy (24).
The biologic basis for a putative increased susceptibili-
ty to certain infections in humans with chronic HTLV-II
infection is not well described. In contrast to the predomi-
nant CD4+ lymphotropism of HTLV-I, HTLV-II provirus
in vivo is integrated at highest levels into CD8+ lympho-
cytes but may also be demonstrated in CD4+, both
CD45RO+ and CD45RO-, and even non-T (CD14, CD16,
and CD19) lymphocytes (25). Delayed hypersensitivity
response to mumps virus and Candida antigens is normal
among HTLV-II participants, suggesting intact cell-medi-
ated or T-helper 1-type immunity (26). Although subtle
differences may exist, the overall distribution of lympho-
cyte subsets is not perturbed in persons with HTLV-II
(27,28). However, total immunoglobulin G levels are high-
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Table 2. Incidence of medically diagnosed conditions and selected unadjusted and adjusted incidence ratios among human T-
lymphotropic virus (HTLV)-I– and HTLV-II– infected participants and HTLV-seronegative participants, visits 2 and 3
a 
HTLV seronegative 
(N = 799)  HTLV-I (N = 152)  HTLV-II (N = 387) 
Diagnosis  Cases (%
b)  Cases (%
b)  IR
c  Adj. IR (95% CI)
d  Cases (%
b)  IR
c  Adj. IR (95% CI)
d 
Pneumonia  25 (3)  5 (4)  0.89  0.79 (0.27 to 2.29)  19 (5)  1.70  1.82 (0.98 to 3.38) 
Acute bronchitis  103 (14)  21 (15)  1.12  1.10 (0.68 to 1.79)  81 (23)  1.83  1.68 (1.24 to 2.29) 
Bladder or kidney infection  105 (14)  31 (23)  1.74  1.82 (1.19 to 2.77)  73 (21)  1.68  1.55 (1.14 to 2.11) 
Arthritis  32 (5)  16 (16)  3.19  2.84 (1.51 to 5.33)  32 (12)  2.51  2.66 (1.58 to 4.45) 
Hypertension  40 (7)  7 (7)  1.06  0.99 (0.44 to 2.22)  20 (7)  1.08  1.09 (0.63 to 1.89) 
Asthma  15 (2)  2 (2)  —  —  20 (6)  3.38  3.28 (1.57 to 6.84) 
Cancer  21 (3)  3 (2)  0.81  0.72 (0.21 to 2.43)  8 (2)  0.87  1.10 (0.44 to 2.32) 
aOnly the first diagnosis of each condition is considered for each participant. IR, incidence ratio derived from survival analysis; CI, confidence interval. 
bDenominator for percentage calculation varied according to the number of participants included in each disease-specific analysis. 
cUnadjusted incidence ratio derived from survival analysis. 
dAfter a backward selection process, including all potential confounding variables, the final survival analysis model contained these variables: age, gender, race/ethnicity, 
and (for pneumonia, bronchitis, and asthma) smoking history (see Methods for details of the statistical analysis). 
Table 3. Incidence density (ID)
a and standard deviation (SD) of medically diagnosed infectious diseases, and selected crude and 
adjusted rate ratios (RR), among human T-lymphotropic virus (HTLV)-I– and HTLV-II–infected participants and HTLV-seronegative 
participants, visits 2 and 3 
HTLV seronegative  
(N = 799)  HTLV-I (N = 152)  HTLV-II (N = 387) 
Diagnosis  ID (SD)  ID (SD)  RR
b  Adj. RR (95% CI)
c  ID (SD)  RR
b  Adj. RR (95% CI)
c 
Pneumonia  0.08 (0.37)  0.11 (0.47)  1.49  1.33 (0.66 to 2.66)  0.21 (0.96)  2.82  2.65 (1.67 to 4.21) 
Acute bronchitis  0.59 (1.78)  0.82 (2.25)  1.38  1.33 (0.84 to 2.12)  1.10 (2.75)  1.83  1.53 (1.10 to 2.14) 
Bladder or kidney infection  0.63 (2.04)  1.75 (4.61)  2.73  2.32 (1.50 to 3.59)  1.25 (3.48)  1.94  1.94 (1.40 to 2.68) 
aDefined as the mean of the total number of infectious disease diagnoses divided by the number of participants (with or without the infection) in each group at baseline. The 
period of observation was 4.4 years (HTLV-I), 4.3 years (HTLV-II), and 4.4 years (HTLV seronegative), and each participant may have multiple diagnoses of each 
condition. 
bUnadjusted. 
cAdjusted. Adjusted models included age, gender, race/ethnicity and duration of follow-up for all infections, and injection drug use (for pneumonia), smoking (for acute 
bronchitis), and community versus autologous blood donation (for bladder/kidney infection). er in HTLV-II-infected persons (29), in vitro cell prolifer-
ation in response to pokeweed mitogen is suppressed in
HTLV-II infection (28), and HTLV-II may induce expres-
sion of interferon-γ, granulocyte macrophage-colony-stim-
ulating factor, and other cytokines (30,31). Although
HTLV-II provirus has also been demonstrated in
macrophages (32), whether such infection influences
macrophage regulation or function to a clinically notable
degree is not known. Finally, lymphocytic pneumonitis has
been reported in association with HTLV-I infection (9,10),
and clinically diagnosed cases of pneumonia and acute
bronchitis in HTLV-II- infected persons could conceivably
represent autoimmune rather than infectious disease.
Our finding of an association of both HTLV-II and
HTLV-I with bladder or kidney infection is consistent with
a previous report of unspecified renal disease in a prospec-
tive cohort study of HTLV-I-infected persons in Japan
(33). However, such associations must be interpreted cau-
tiously in light of the known association of both retrovirus-
es with HTLV-associated myelopathy (5,34,35). Since uri-
nary frequency and urgency are among the first symptoms
of bladder hyperreactivity due to the underlying myelopa-
thy, HTLV-I- or -II-infected persons might seek medical
care for these symptoms. Urinary tract infection or kidney
disease secondary to unrecognized neurogenic bladder
dysfunction might be diagnosed, or they may be treated
presumptively for urinary tract infection on the basis of
their bladder symptoms. In either case, an increased inci-
dence of diagnosed bladder or kidney infection may not
necessarily indicate that HTLV-I or -II infection is the
cause of these urinary infections. Finally, although we con-
trolled for the number of sexual partners, residual con-
founding by sexual activity could have influenced our
bladder or kidney infection finding (36).
The increased incidence of arthritis observed for both
persons infected with HTLV-I and HTLV-II supports
reports of possible autoimmune syndromes with HTLV
infection. HTLV-I has been epidemiologically associated
with uveitis (8). Several previous reports of HTLV-I in
case series of arthritis have been limited by the lack of
appropriate controls (11,12). Nonetheless, high numbers of
HTLV-I-infected lymphocytes have been demonstrated in
synovial fluid from some of these case-patients. Although
we obtained medical records to verify arthritis and other
diagnoses, the records did not give sufficient information
to classify the type of arthritis and diagnostic evaluations
were limited in most cases. Although an association
between HTLV-I infection and asthma has been reported
among Japanese men (13), we are unaware of previous
reports of an increased incidence of asthma in association
with HTLV-II infection. Also, a few cases of lymphocytic
pneumonitis have been reported in patients with HTLV-I
infection, particularly those with myelopathy (9,10).  We
plan a more intensive diagnostic evaluation of the HTLV-
II participants in this study with recurrent pneumonia or
asthma to explore the possible contribution of undiagnosed
lymphocytic pneumonitis to the observed clinical signs
and symptoms.
We have previously reported a single case of adult T-
cell leukemia which was diagnosed between the first and
second visits of the patient in this cohort study (17); no
additional cases have been diagnosed to date. That neither
HTLV-I nor -II participants had an increased incidence of
nonhematologic cancer in our current analysis is potential-
ly reassuring to persons infected with these retroviruses.
However, an increased incidence of some cancers, espe-
cially those thought to be induced by viruses, has been
reported in a Japanese HTLV-I cohort (37).  We might not
have detected a small increase in IR because of the rela-
tively small number of cases detected during our 4.3-year
follow-up period. Alternatively, we might not have had
enough HTLV-I or -II participants who were co-infected
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Table 4. Prevalence of medically diagnosed symptoms, and unadjusted and adjusted odds ratios (OR) derived from logistic 
regression models, in human T-lymphotropic virus (HTLV)-I– and HTLV-II–infected participants and HTLV-seronegative participants, 
visits 2 and 3
a 
HTLV seronegative  
(N = 799)  HTLV-I (N = 152)  HTLV-II (N = 387) 
Symptoms  Cases (%)
b  Cases (%)
b  OR
c  Adj. OR (95% CI)
d  Cases (%)
b  OR
c  Adj. OR (95% CI)
d 
Trouble walking, climbing 
or rising from chair  147 (21)  52 (42)  2.71  2.67 (1.74 to 4.09)  133 (42)  2.78  3.44 (2.52 to 4.71) 
Incontinence, pre- or post-
void urgency  175 (25)  50 (40)  2.03  2.02 (1.33 to 33.07)  134 (43)  2.25  2.59 (1.92 to 3.49) 
Lymphadenopathy  29 (4)  11 (9)  2.26  2.39 (1.14 to 5.03)  40 (13)  3.40  3.08 (1.85 to 5.13) 
Night sweats  20 (3)  15 (12)  4.68  4.73 (2.31 to 9.69)  47 (15)  6.02  4.97 (2.77 to 8.94 
Weight loss  40 (6)  9 (7)  1.29  1.10 (0.51 to 2.37)  40 (13)  2.43  2.10 (1.22 to 3.60) 
Foot paresthesias  57 (8)  22 (18)  2.44  2.46 (1.41 to 4.28  66 (21)  3.02  3.27 (2.19 to 4.88) 
Impotence (males only)  33 (5)  10 (8)  2.24  2.05 (0.77 to 5.49)  13 (4)  1.10  1.27 (0.56 to 2.91) 
aOnly the first diagnosis of each symptom is considered for each participant. 
bDenominator for percentage calculation varied according to the number of participants included in each disease-specific analysis. 
cUnadjusted.  
dAdjusted. Models were adjusted for age, race and ethnicity, and duration of follow-up (all symptoms), and gender (all except impotence). In addition, specific models 
included community versus autologous donation (for trouble walking and incontinence, weight loss and impotence) and injection drug use [night sweats and weight loss]). with other oncogenic viruses such as hepatitis C virus to
detect a synergistic effect between HTLV-I or -II and these
viruses (38).
The two- to three-fold higher prevalence of self-report-
ed neurologic symptoms, including trouble walking,
climbing stairs, or rising from a chair, and bladder symp-
toms may represent early spinal cord injury due to HTLV-
I or -II. As follow-up of the cohort continues, we shall be
able to determine whether those reporting such symptoms
in earlier visits have a higher incidence of overt myelopa-
thy than asymptomatic HTLV-infected participants. On the
other hand, the frequency of self-reported lymphadenopa-
thy and night sweats is unlikely to be caused by preclinical
hematologic malignancy, given the rarity of that disorder
in HTLV-I–infected persons and its lack of association
with HTLV-II. These symptoms might be related to known
effects of HTLV-I and -II on lymphocytic proliferation and
cytokine expression, or they might simply reflect reporting
bias.
Strengths of the current study include its controlled,
prospective, cohort design, stringent confirmation of
HTLV-I– and -II–infection status at baseline, and system-
atic ascertainment of disease outcomes. One potential
weakness is that differences in socioeconomic status and
risk behaviors could have confounded disease associations
between HTLV–infected and uninfected previous blood
donors, even though we selected the uninfected partici-
pants in strata defined by the age, sex, race or ethnicity,
center, and blood donation type of the HTLV groups. We
controlled for the socioeconomic and behavioral factors
using multivariate analyses, but residual confounding
could affect the magnitude of the associations we
observed. Second, recall bias may exist in that participants
with HTLVinfection might differentially report more diag-
noses because of heightened concern about their own
health. Our questionnaire requested only medically con-
firmed diagnoses, and the absence of associations with
noninfectious disease, such as hypertension, diabetes, and
thyroid disease, suggests that generalized overreporting of
illness was not a problem. Additionally, infectious disease
associations with HTLV have not been widely reported, so
we do not think that recall bias specific to these diagnoses
was a serious concern. Finally, follow-up time to date is
modest for a chronic infection such as HTLV, and our find-
ings may change with longer observation.
In conclusion, HTLV-II infection is associated with an
increased incidence of respiratory and urinary tract infec-
tions and asthma, and both HTLV-I and -II are associated
with increased incidence rates of arthritis, compared with
results for seronegative persons. These findings suggest
that chronic infection with HTLV-II may inhibit host
immunologic responses to infection, or more specifically,
to respiratory infections. The arthritis and asthma results,
and possibly the respiratory tract diagnoses, suggest that
other inflammatory or autoimmune reactions may be
induced by HTLV-I or HTLV-II infection. Additional in
vitro and in vivo research on the immunologic conse-
quences of HTLV infection is needed.
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